康希诺生物(06185)Td5cp疫苗获准在4至5岁人群开展临床试验

公告速递
4 hours ago

2026年11月16日,康希诺生物股份公司(06185)发布自愿公告称,其自主研发的吸附无细胞百(五组分)白破联合疫苗Td5cp已获国家药品监督管理局批准,可在4至5岁人群中开展相关临床试验。

公告指出,随着全剂量共纯化DTaP疫苗接种针次和接种年龄的增加,不良反应发生率及严重程度均有所上升。国际上普遍采用抗原含量降低的Tdap疫苗自4岁起进行加强接种,以降低不良反应风险。

此次临床试验申请拟将Td5cp的6岁加强免疫年龄扩展至4至6岁,以激发免疫记忆,使抗体水平迅速回升至有效保护范围。公司称,此举有助于填补入学前的免疫空白,并降低托幼机构与小学的暴发风险,为建立全年龄免疫屏障、控制百日咳传播提供支持。

公司提醒股东及潜在投资者在买卖公司股份时保持审慎。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10